This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Synergy Pharmaceuticals, Inc.
Drug Names(s): Atiprimod
Description: Atiprimod is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity.
Deal Structure: In August 2002, Callisto's wholly owned subsidiary, Synergy, acquired from AnorMED worldwide exclusive rights to develop, manufacture and commercialize Atiprimod.
AnorMED was acquired by Genzyme in November 2006.
In January 2008, Callisto Pharmaceuticals announced that it restructured its license agreement with Genzyme for Atiprimod. The restructured agreement eliminates all milestone payments and reduces royalties owed to Genzyme to single digits. In return for the reduced future payments to Genzyme, Callisto is paying an upfront fee in 2008.
On December 19, 2008, Callisto announced a Technology Assignment Agreement with AnorMED, a wholly-owned subsidiary of Genzyme, acquiring all rights to atiprimod in return for a cash payment of $650,000 from Callisto. Pursuant to the Technology Assignment Agreement, the earlier Amended and Restated License Agreement between Callisto and AnoMED dated December 31, 2007 was terminated.
In October 2010, Sanofi-aventis announced it has...See full deal structure in Biomedtracker
Additional information available to subscribers only: